IL-10 regulation of lupus in the NZM2410 murine model

Laboratory Investigation

Volumn 86, Issue 11, 2006, Pages 1136-1148

  Blenman, Kim R M ^a   Duan, Byian ^a   Xu, Zhiwei ^a   Wan, Suigui ^a   Atkinson, Mark A ^a   Flotte, Terence R ^a   Croker, Byron P ^a,b   Morel, Laurence ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

AAV; Gene therapy; IL 10; Inflammation; Lupus

Indexed keywords

ANTINUCLEAR ANTIBODY; INTERLEUKIN 10; PARVOVIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; CONTROLLED STUDY; DISEASE MARKER; FEMALE; GENE LOCUS; GENE OVEREXPRESSION; GENE TARGETING; GENE THERAPY; GENETIC SUSCEPTIBILITY; LUPUS ERYTHEMATOSUS NEPHRITIS; MOUSE; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; SKELETAL MUSCLE; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; VIRAL GENE DELIVERY SYSTEM;

EID: 33750341662     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.3700468     Document Type: Article

References (52)

1. Mocellin S, Marincola F, Rossi CR, et al. The multi-faceted relationship between IL-10 and adaptive immunity: putting together the pieces of a puzzle. Cytokine Growth Factor Rev 2004;15:61-76.
2. Hagiwara E, Gourley MF, Lee S, et al. Disease severity in patients with systemic lupus erythematosus correlates with an increased ratio of interleukin-10: Interferon-gamma-secreting cells in the peripheral blood. Arthritis Rheum 1996;39:379-385.
3. Alarcon-Riquelme ME, Lindqvist AKB, Jonasson I, et al. Genetic analysis of the contribution of IL10 to systemic lupus erythematosus. J Rheumatol 1999;26: 2148-2152.
4. Grondal G, Kristjansdottir H, Gunnlaugsdottir B, et al. Increased number of interleukin-10-producing cells in systemic lupus erythematosus patients and their first-degree relatives and spouses in Icelandic multicase families. Arthr Rheumat 1999;42:1649-1654.
5. Gibson AW, Edberg JC, Wu J, et al. Novel single nucleotide polymorphisms in the distal IL-10 promoter affect IL-10 production and enhance the risk of systemic lupus erythematosus. J Immunol 2001;166:3915-3922.
6. Mageed RA, Prud'homme GJ. Immunopathology and the gene therapy of lupus. Gene Therapy 2003;10:861-874.
7. Ishida H, Muchamuel T, Sakaguchi S, et al. Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice. J Exp Med 1994;179:305-310.
8. Yin ZN, Bahtiyar G, Zhang N, et al. IL-10 regulates murine lupus. J Immunol 2002;169:2148-2155.
9. Rudofsky UH, Evans BD, Balaban SL, et al. Differences in expression of lupus nephritis in New-Zealand mixed H-2(Z) homozygous inbred strains of mice derived from New-Zealand black and New-Zealand white mice-origins and initial characterization. Lab Invest 1993;68:419-426.
10. Morel L, Rudofsky UH, Longmate JA, et al. Polygenic control of susceptibility to murine systemic lupus erythematosus. Immunity 1994;1:219-229.
11. Morel L, Croker BP, Blenman KR, et al. Genetic reconstitution of systemic lupus erythematosus immunopathology with polycongenic murine strains. Proc Natl Acad Sci USA 2000;97:6670-6675.
12. Xu Z, Duan B, Croker BP, et al. Genetic dissection of the murine lupus susceptibility locus Sle2: contributions to increased peritoneal B-1a cells and lupus nephritis map to different loci. J Immunol 2005;175:936-943.
13. O'Garra A, Chang R, Go N, et al. Ly-1 B (B-1) cells are the main source of B cell-derived interleukin 10. Eur J Immunol 1992;22:711-717.
14. Moore KW, Waal-Malefyt R, Coffman RL, et al. Interleukin-10 and the interleukin-10 receptor. Ann Rev Immunol 2001;19:683-765.
15. Rabinowitz JE, Samulski J. Adeno-associated virus expression systems for gene transfer. Curr Opin Biotech 1998;9:470-475.
16. Kessler PD, Podsakoff GM, Chen XJ, et al. Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. Proc Natl Acad Sci USA 1996;93:14082-14087.
17. Flotte TR. Adeno-Associated Virus-based gene therapy for inherited disorders. Pediatr Res 2005;58:1143-1147.
18. Yamano S, Scott DE, Huang LY, et al. Protection from experimental endotoxemia by a recombinant adeno-associated virus encoding interleukin 10. J Gene Med 2001;3:450-457.
19. Apparailly F, Millet V, Noel D, et al. Tetracycline-inducible interleukin-10 gene transfer mediated by an adeno-associated virus: application to experimental arthritis. Hum Gene Ther 2002;13:1179-1188.
20. Jennings K, Miyamae T, Traister R, et al. Proteasome inhibition enhances AAV-mediated transgene expression in human synoviocytes in vitro and in vivo. Mol Ther 2005;11:600-607.
21. Yoshioka T, Okada T, Maeda Y, et al. Adeno-associated virus vector-mediated interleukin-10 gene transfer inhibits atherosclerosis in apolipoprotein E-deficient mice. Gene Therapy 2004;11:1772-1779.
22. Watanabe M, Kashiwakura Y, Kusumi N, et al. Adeno-associated virus-mediated human IL-10 gene transfer suppresses the development of experimental autoimmune orchitis. Gene Therapy 2005;12:1126-1132.
23. Broderick CA, Smith AJ, Balaggan KS, et al. Local administration of an adeno-associated viral vector expressing IL-10 reduces monocyte infiltration and subsequent photoreceptor damage during experimental autoimmune uveitis. Mol Ther 2005;12:369-373.
24. Smith JR, Verwaerde C, Rolling F, et al. Tetracycline-inducible viral interleukin-10 intraocular gene transfer, using adeno-associated virus in experimental autoimmune uveoretinitis. Hum Gene Ther 2005;16:1037-1046.
25. Mu W, Ouyang X, Agarwal A, et al. IL-10 suppresses chemokines, inflammation, and fibrosis in a model of chronic renal disease. J Am Soc Nephrol 2005;16: 3651-3660.
26. Goudy K, Song SH, Wasserfall C, et al. Adeno-associated virus vector-mediated IL-10 gene delivery prevents type 1 diabetes in NOD mice. Proc Natl Acad Sci USA 2001;98:13913-13918.
27. Zhang YC, Pileggi A, Agarwal A, et al. Adeno-associated virus-mediated IL-10 gene therapy inhibits diabetes recurrence in syngeneic islet cell transplantation of NOD mice. Diabetes 2003;52:708-716.
28. Yang Z, Chen M, Wu R, et al. Suppression of autoimmune diabetes by viral IL-10 gene transfer. J Immunol 2002;168:6479-6485.
29. Carter JD, Chen M, Ellett JD, et al. Impact of donor immune cells in pancreatic islet transplantation. Transpl Proc 2004;36:2866-2868.
30. Goudy KS, Burkhardt BR, Wasserfall C, et al. Systemic overexpression of IL-10 induces CD4(+)CD25(+) cell populations in vivo and ameliorates type 1 diabetes in nonobese diabetic mice in a dose-dependent fashion. J Immunol 2003;171:2270-2278.
31. Singh RR, Saxena V, Zang S, et al. Differential contribution of IL-4 and STAT6 vs STAT4 to the development of lupus nephritis. J Immunol 2003;170:4818-4825.
32. Xia CQ, Kao KJ. Induction of immune tolerance across major histocompatibility complex barrier by transfusion of ultraviolet B-irradiated immature dendritic cells. Transfusion 2005;45:181-188.
33. Hauswirth WW, Lewin AS, Zolotukhin S, et al. Production and purification of recombinant adeno-associated virus. Methods Enzymol 2000;316: 743-761.
34. Weening JJ, D'Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004;15: 241-250.
35. Quigg RJ. Complement and autoimmune glomerular diseases. Curr Dir Autoimm 2004;7:165-180.
36. Erickson LD, Lin LL, Duan B, et al. A genetic lesion that arrests plasma cell homing to the bone marrow. Proc Natl Acad Sci USA 2003;100:12905-12910.
37. Mohan C, Yu Y, Morel L, et al. Genetic dissection of Sle pathogenesis: Sle3 on murine chromosome 7 impacts T cell activation, differentiation, and cell death. J Immunol 1999;162:6492-6502.
38. Chen Y, Cuda C, Morel L. Genetic determination of T cell help in loss of tolerance to nuclear antigens. J Immunol 2005;174:7692-7702.
39. Emilie D, Zou W, Fior R, et al. Production and roles of IL-6, IL-10, and IL-13 in B-lymphocyte malignancies and in B-lymphocyte hyperactivity of HIV infection and autoimmunity. Methods 1997;11:133-142.
40. Brummel R, Lenert P. Activation of marginal zone B cells from lupus mice with type A(D) CpG-oligodeoxynucleotides. J Immunol 2005;174:2429-2434.
41. Lenert P, Brummel R, Field EH, et al. TLR-9 activation of marginal zone B Cells in lupus mice regulates immunity through increased IL-10 production. J Clin Immunol 2005;25:29-40.
42. Mizoguchi A, Bhan AK. A case for regulatory B cells. J Immunol 2006;176:705-710.
43. Hayakawa K, Hardy RR, Herzenberg LA. Peritoneal Ly-1 B-Cells-Genetic- Control, Autoantibody Production, Increased Lambda Light Chain Expression. Eur J Immunol 1986;16:450-456.
44. Mohan C, Morel L, Yang P, et al. Accumulation of splenic B1a cells with potent antigen-presenting capability in NZM2410 lupus-prone mice. Arthr Rheumat 1998;41:1652-1662.
45. Xu Z, Duan B, Croker BP, et al. STAT4 deficiency reduces autoantibody production and glomerulonephritis in a mouse model of lupus. Clin Immunol 2006;120:189-198.
46. Waters ST, McDuffie M, Bagavant H, et al. Breaking tolerance to double stranded DNA, nucleosome, and other nuclear antigens is not required for the pathogenesis of lupus glomerulonephritis. J Exp Med 2004;199:255-264.
47. Rousset F, Garcia E, Defrance T, et al. Interleukin-10 is a potent growth and differentiation factor for activated human lymphocytes-B. Proc Natl Acad Sci USA 1992;89:1890-1893.
48. Levy Y, Brouet JC. Interleukin-10 prevents spontaneous death of germinal center B-cells by induction of the Bcl-2 protein. J Clin Invest 1994;93:424-428.
49. Kuhn R, Lohler J, Rennick D, et al. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993;75:263-274.
50. Watanabe N, Ikuta K, Nisitani S, et al. Activation and differentiation of autoreactive B-1 cells by interleukin 10 induce autoimmune hemolytic anemia in Fas-deficient antierythrocyte immunoglobulin transgenic mice. J Exp Med 2002;196:141-146.
51. Zhu JK, Liu XB, Xie C, et al. T cell hyperactivity in lupus as a consequence of hyperstimulatory antigen-presenting cells. J Clin Invest 2005;115:1869-1878.
52. Roncarolo MG, Bacchetta R, Bordignon C, et al. Type 1 T regulatory cells. Immunol Rev 2001;182:68-79.